Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 365 clinical trials
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

In this study the investigators assess the impact of the eHealth-supported therapy management system CANKADO on Quality of Life in patients with HR+, HER2-locally advanced or metastatic breast

fulvestrant
endocrine therapy
exemestane
aromatase inhibitor
breast cancer
  • 45 views
  • 27 Jan, 2021
  • 1 location
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual …

  • 139 views
  • 03 Mar, 2021
  • 482 locations
Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer

metastatic breast cancer, stereotactic radiosurgery, also known as stereotactic body radiation therapy, may be able to send x-rays directly to the tumor and cause less damage to normal tissue and surgery may

endocrine therapy
bone scan
x-rays
neutrophil count
ct scan
  • 574 views
  • 07 Mar, 2021
  • 84 locations
A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

docetaxel in patients who have HER2 positive metastatic breast cancer and have not received systemic anticancer therapy for advanced disease.

trastuzumab
measurable disease
breast cancer
HER2
metastasis
  • 0 views
  • 25 Jan, 2021
  • 1 location
Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Primary Objective: To determine whether amcenestrant per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

fulvestrant
endocrine therapy
breast adenocarcinoma
exemestane
immunological adjuvant
  • 213 views
  • 28 Feb, 2021
  • 164 locations
Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial

A pragmatic randomized clinical trial of patients with locally advanced breast cancer randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and mortality, health-related quality of life, and cancer control outcomes. Quality of life is the outcome measure for the estimated primary completion date of August, …

stage iv breast cancer
carcinoma
lumpectomy
mastectomy
locally advanced breast cancer
  • 41 views
  • 27 Jan, 2021
  • 35 locations
  • 148 views
  • 05 Mar, 2021
  • 38 locations
Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)

This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and safety of Sacituzumab Govitecan versus TPC in subjects with metastatic or locally recurrent inoperable HR+/HER2- MBC, after failure of at least 2, and no more than 4, prior chemotherapy regimens for metastatic disease.

vinorelbine
capecitabine
eribulin
cancer chemotherapy
HER2
  • 66 views
  • 07 Mar, 2021
  • 105 locations
The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

metastatic breast cancer and non-visceral disease.

endocrine therapy
everolimus
exemestane
immunostimulant
breast cancer
  • 101 views
  • 28 Feb, 2021
  • 146 locations
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

. Participants in this study have metastatic breast cancer. This means the cancer has spread to other parts of the body.

advanced breast cancer
stage iv breast cancer
breast cancer
HER2
erbb2
  • 179 views
  • 26 Jan, 2021
  • 56 locations